(Q50592808)

16 March 2018

title

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. (English)

1 reference

16 March 2018

1 reference

1 reference

1 reference

Neil E Fleshner

1

1 reference

16 March 2018

M Scott Lucia

2

1 reference

16 March 2018

Blair Egerdie

3

1 reference

16 March 2018

Lorne Aaron

4

1 reference

16 March 2018

Gregg Eure

5

1 reference

16 March 2018

Indrani Nandy

6

1 reference

16 March 2018

Libby Black

7

1 reference

16 March 2018

Roger S Rittmaster

8

1 reference

16 March 2018

language of work or name

English

0 references

publication date

24 January 2012

1 reference

16 March 2018

published in

The Lancet

1 reference

16 March 2018

volume

379

1 reference

16 March 2018

issue

9821

1 reference

16 March 2018

page(s)

1103-1111

1 reference

16 March 2018

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Prostate cancer prevention: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Screening and prostate-cancer mortality in a randomized European study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Outcomes of localized prostate cancer following conservative management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Effect of dutasteride on the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Delayed versus immediate surgical intervention and prostate cancer outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Impact of 5α-Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Clinical events in prostate cancer lifestyle trial: results from two years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Estimating rates of true high-grade disease in the prostate cancer prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961619-X

7 January 2021

10.1016/S0140-6736(11)61619-X

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018